Association between XRCC3 Thr241Met Polymorphism and the Risk of Cancer in Northern Brazil

Suzane da Silva Cabral¹, Lorrayne Lacerda Lobato¹, Rafael Espíndola do Nascimento¹, Olavo Magalhães Picanço Júnior¹ and Artemis Socorro do Nascimento Rodrigues¹

¹Department of Biological Sciences, Laboratory of Molecular Biology and Biotechnology, Federal University of Amapá, Highway Juscelino Kubitschek, Garden Ground Zero, KM-02, CEP 68.903-419 -s/n - Macapá, AP, Brazil.

Authors’ contributions

This work was carried out in collaboration between all authors. All authors read and approved the final manuscript.

Article Information

DOI: 10.9734/BJMMR/2016/24667

Original Research Article

ABSTRACT

Aims: Cancer is a genetic disease characterized by an unbalance between cell growth and regulatory factors. The gene XRCC3 encodes a protein that contributes to the integrity of the genome and XRCC3 Thr241Met variants have their capacity of repair altered.

Study Design: Our goal was to evaluate XRCC3 241Met polymorphism in a sample of cancer patients in the city of Macapá.

Place and Duration of Study: Laboratory of Molecular Biology (Biological Sciences Program of the Federal University of Amapá), Dr. Alberto Lima Clinical Hospital (Hcal) and Institute of Hematology and Hemotherapy of Amapá between June 2009 and July 2010.

Methodology: We analyzed 100 DNA samples of patients (50 cases diagnosed with cancer and 50 controls). DNA samples were amplified and analyzed by PCR-RFLP with the enzyme NLaIII.

*Corresponding author: E-mail: artemis@unifap.br;
**Results:** The molecular analysis revealed that 58% of cases and 12% of controls had the Thr/Met genotype, while 82% of controls and 36% of cases had the Thr/Thr genotype.

**Conclusion:** Non-invasive independent predictors for screening esophageal varices may decrease medical as well as financial burden, hence improving the management of cirrhotic patients. These predictors, however, need further work to validate reliability. The frequency of the Thr/Met genotype was higher among cancer patients when compared to the control group. Our findings suggest that XRCC3 241Met polymorphism may be associated with the risk cancer in the study population.

**Keywords:** Cancer; gene polymorphism; XRCC3 gene; Macapá.

1. INTRODUCTION

Cancer is a genetic disease characterized by a disruption of the complex balance between cell growth and the factors that participate in this process. Cell growth may be initiated and continued as the result of mutations in the genes responsible for the maintenance of homeostatic cell proliferation [1,2]. These alterations might be caused by exposure to carcinogens, random replication errors, and defective DNA repair mechanisms [1,3].

Repair pathways maintain the integrity of the genome against environmental aggressors and replication errors through four main mechanisms: Nucleotide excision repair (NER), base excision repair (BER), double strand break repair (DSBR), and mismatch repair (MMR). Associated to these pathways, more than 100 proteins have been identified in human cells [4-6].

The X-ray repair cross-complementing group 3 gene (XRCC3), located at 14q32.3 in the human chromosome, encodes a protein with the same name. This protein consists of 346 amino acids and participates in the maintenance of chromosome stability and the formation of heteroduplex DNA, by repairing double strand breaks (DSBs) through homologous recombination (HR) associated to RAD-51. To perform its function in the initial phase of this process, XRCC3 carries out homology searches in the intact molecule, invading the chain for the synthesis of DNA [6-13]. The most frequent polymorphism of this gene involves the substitution of Threonine (Thr) with Methionine (Met) in the codon 241 of exon 7. Variants of Thr241Met have impaired enzymatic function, altering their DNA repair capacity [6,13-15].

Several studies have associated these variants with some types of cancer, such as breast [16], gastric [17,18], lung [19-21], melanomas [22], oral cavity [23] and bladder [19,24] cancers. This study was aimed at examining a possible association between XRCC3 Thr241Met polymorphism and the risk of cancer among individuals in a city in the Amazon region.

2. MATERIALS AND METHODS

We analyzed 100 samples of peripheral blood from 50 cancer patients from the Dr. Alberto Lima Clinical Hospital (Hcal) from 30 samples are from patients with gastric cancer and the remaining patients with breast and prostate cancer, in the city of Macapá and 50 blood donors of the Institute of Hematology and Hemotherapy of Amapá (Instituto de Hematologia e Hemoterapia do Amapá – HEMOAP) after signing an Informed Consent Form.

Blood samples were analyzed at the Laboratory of Molecular Biology of the Biological Sciences Program of the Federal University of Amapá (Universidade Federal do Amapá – UNIFAP) for the identification of genetic polymorphism in the gene XRCC3.

The procedure to isolate the DNA from blood samples followed the protocol recommended by Invitrogen, the manufacturer of Genomic DNA Mini Kit. XRCC3 241Thr/Thr homozygotes have a 208-bp fragment; Thr/Met heterozygotes have 208, 120 and 88-bp fragment; and Met/Met homozygotes 120 and 88-bp fragments. The samples were amplified and analyzed by PCR-RFLP. The PCR chain reaction for the XRCC3 gene was carried out according to the method described by Shen. et.al (2004). The primers used to amplify the 208 pb fragment were 241F: 5-GCTGTCTCGGGGCATGGCTC-3 and 241R: 5-ACGAGCTCAAGGGGTGCAACC-3. The enzyme used was NlaIII (New England Biolabs, Beverly, MA). The conditions for 23 µl of PCR were: 1.0 µl of each primer, 2.0 µl of genomic DNA, 0.5 µl of Taq DNA polymerase, 11.5 µl of H2O, 5 ul of buffer solution, and 2 ul of dNTP.
The amplification cycle was carried out at 94°C for 5 minutes, 30 cycles at 94°C for 30 seconds, 59°C for 30 seconds, and 72°C for 1 minute, final extension for 10 minute at 72°C and 4°C. After the amplification reaction, 10 µl of the PCR product were digested with 1 µl of the enzyme NlaIII (New England Biolabs, Beverly, MA), 1.0 µl of buffer, 2 µl of sterile water at 37°C for one night and later subjected to electrophoresis for the identification of fragments.

The results were analyzed by statistical tests $\chi^2$ using BioEstat 5.3 program to compare the distribution of genotype frequencies between the cases and controls. The association between XRCC3 genotype and gastric cancer was estimated by computing odds ratios (ORs) and 95% confidence intervals (CIs) from multivariate logistic regression analyses.

### 3. RESULTS AND DISCUSSION

Fifty DNA samples of cancer patients and 50 samples of the control group were analyzed and our findings demonstrated that 58% (0.091 (0.032 - 0.257) of patients had the Thr/Met genotype, while in the control group, the frequency of this genotype was only 12%. The frequency of the genotype Thr/Thr was 36% and 82% in case and controls, respectively. For the genotype Met/Met, the frequency observed was 6% in both groups (Table 1).

The gene XRCC3 plays an important role in the repair mechanism by homologous recombination of double strand breaks (DSBs) caused by ionizing irradiation and reactive oxygen species. These are some of the most DNA-damaging agents and frequently lead to apoptosis and loss of genetic material [6,25,26]. Given the importance of this DNA repair mechanism, it is biologically reasonable that a genetic polymorphism might modulate the risk of development of many types of cancer [6,17,25].

In the present study, we investigated the association between XRCC3 Thr241Met polymorphism and the risk of cancer. The study of this polymorphism in specific populations is justified by the wide regional differences in its effect on the risk of developing cancer. In a meta-analysis, Lee et al. [27] found a low association between this polymorphism and susceptibility to breast cancer among Korean women. However, Qureshi et al. [28] reported an increased risk associated with this polymorphism in Pakistani women.

Regarding the frequency of Thr/Thr, our results revealed that 36% of cancer patients had this genotype, compared to 82% of the control group. This demonstrates that the frequency of this wild genotype is higher in healthy individuals than in those diagnosed with cancer (Table 1) [6,17,29,30].

Among patients diagnosed with malignant neoplasms, only 6% had the homozygous genotype Met/Met. This was also observed by He et al. [6] in a meta-analysis, suggesting that the allele met has a low association with risk of cancer (except breast and bladder cancers), contrary to the expected based on the biochemical properties associated with XRCC3 Thr241Met polymorphism. When an association with susceptibility to gastric cancer was examined, a strong relationship was found between this genotype and non-cardia gastric cancer but not with cardia cancer [18].

Regarding Thr/Met, 58% of cancer patients and 12% of individuals of the control group had this heterozygous genotype (0.91 (0.32 – 2.05). This is in agreement with Bastos et al. [31] that found a significant association between XRCC3 Thr/Met polymorphism and the risk of developing thyroid cancer in the Chinese population, mainly among smokers and alcohol consumers [32]. Fang et al. [33] carried out a meta-analysis and found a similar pattern in all six studies examined, with heterozygosis with the strongest association with susceptibility to gastric cancer.

### Table 1. Frequency of the XRCC3 Thr241Met variants in cases and controls

| Genotype   | Case (n = 50) | Control (n = 50) | OR (95% CI) |
|------------|--------------|-----------------|-------------|
|            | Nº. (%)      | Nº. (%)         | Crude       |
| XRCC3 Thr241Met |              |                 |             |
| Thr/Thr    | 18 (36)      | 41 (82)         | 1.00        |
| Thr/Met    | 29 (58)      | 6 (12)          | 0.91 (0.32 – 2.05) |
| Met/Met    | 3 (6)        | 6 (12)          | 1.0         |

$\chi^2 = 24.080, p < 0.001$ (Genotype: Thr/Thr vs Thr/Met);
$\chi^2 = 0.946, p = 0.331$ (Genotype: Thr/Thr vs Met/Met);
$\chi^2 = 3.228, p < 0.072$ (Genotype Thr/Met vs Met/Met);
4. CONCLUSION

The present study found evidences that support the reported in other studies on the association between polymorphism in the repair gene XRCC3 and the risk of cancer. Our results revealed that the frequency of the genotype Thr/Met was higher in cancer patients when compared to the control group and the time interval analysis set forth that the polymorphism likely to occur within 1 year in our population is 52.35%. Given the sample size of our study, further molecular studies on the genotype 241Met and the risk of cancer in other populations are needed to confirm this association. Despite this our results were statistically significant to elucidate the role of these polymorphisms in carcinogenesis.

CONSENT

All authors declare that written informed consent was obtained from all the patient.

ETHICAL APPROVAL

All authors hereby declare that all experiments have been examined and approved by the appropriate ethics committee and have therefore been performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki.

COMPETING INTERESTS

Authors have declared that no competing interests exist.

REFERENCES

1. Morin PJ, Trent JM, Collins FS, Vogelstein B. Cancer genetics. In: Longo DL, Fauci AS, Kasper DL, Hauser SL, Jameson JL, Loscalzo J, editors. Harrison's Principles of Internal Medicine, 18th ed. McGraw-Hill Professional; 2011.
2. Adkison LR, Brown MD. Genética. 1st Ed Rio De Janeiro: Elsevier; 2008.
3. Jin G, Wang M, Chen W, Shi W, Yin J, Gang W. Single nucleotide polymorphisms of nucleotide excision repair and homologous recombination repair pathways and their role in the risk of osteosarcoma. Pak J Med Sci, Taizhou. 2015;31(2):269-273. DOI: 10.12669/pjms.312.6569
4. Li J-T, Zhong B-W, Xu H-H, Qiao S-Y, Wang G, Huang J, et al. Associations between NBS1 polymorphisms and colorectal cancer in Chinese population. Plos One. 2015;10(7):e0132332. DOI: 10.1371/journal.pone.0132332
5. Duarte MC, Colombo J, Rossit ARB, Caetano A, Borim AA, Wornrath D, et al. Polymorphisms of DNA repair genes XRCC1 and XRCC3, interaction with environmental exposure and risk of chronic gastritis and gastric cancer. World Journal of Gastroenterology. 2005;11(42):6593-6600.
6. He X-F, Wei W, Li J-L, Shen X-L, Ding D-P, Wang S-L, et al. Association between the XRCC3 T241M polymorphism and risk of cancer: Evidence from 157 case-control studies. Gene. 2013;523(1):10-19. DOI: 10.1016/j.gene.2013.03.071
7. Christmann M, Tomicic MT, Roos WP, Kaina B. Mechanisms of human DNA repair: An update. Toxicology. 2003; 193(1-2):3-34. DOI: 10.1016/S0300-483X(03)00287-7
8. Dianov GL, Sleeth KM, Dianova II, Allinson SL. Repair of abasic sites in DNA. Mut Res. 2003;531(1-2):157-163. DOI: 10.1016/j.mrfmmm.2003.09.003
9. Brenneman MA, Wagener BM, Miller CA, Allen C, Nickoloff JA. XRCC3 controls the fidelity of homologous recombination: Roles for XRCC3 in late stages of recombination. Moll Cell. 2002;10(2):387-395. DOI: 10.1016/S1097-2765(02)00595-6
10. Thompson LH, Schild D. Recombinational DNA repair and human disease. Mutat Res. 2002;509(1-2):49-78. DOI: 10.1016/S0027-5107(02)00224-5
11. Schild D, Lio Y-C, Collins DW, Tsomondo T, Chen DJ. Evidence for simultaneous protein interactions between human RAD-51 paralogs. J Biol Chem. 2000;275(22):16443-16449. DOI: 10.1074/jbc.M001473200
12. Bishop DK, Ear U, Bhattacharyya A, Calderone C, Beckett M, Weichselbaum RR, et al. XRCC3 is required for assembly of Rad51 complexes in vivo. J Biol Chem. 1998;273(34):21482-21488.
13. Shen MR, Jones IM, Mohrenweiser H. Non-conservative amino acid substitution variants exist at polymorphic frequency in DNA repair genes in healthy humans. Cancer Res. 1998;58(4):604-608.
14. Fan J, Fan Y, Kang X, Zhao L. XRCC3 T241M polymorphism and melanoma skin
cancer risk: A meta-analysis. Oncology Letters. 2015;9(5):2425-2429.

15. Areeshi MY. Genetic variation in a DNA double strand break repair gene in saudi population: A comparative study with worldwide ethnic groups. Asian Pacific Journal of Cancer Prevention. 2013;14(12):7091-7094.

16. Economopoulos KP, Sergentanis TN. XRCC3 Thr241Met polymorphism and breast cancer risk: A meta-analysis. Breast Cancer Res Treat. 2010;121(2):439-443.

17. Gok I, Baday M, Çetinkünar S, Kiliç K, Bilgin BC. Polymorphisms in DNA repair genes XRCC2 and XRCC3 risk of gastric cancer in Turkey. Bosn J Basic Med Sci. 2014;14(4):214-218.

18. Qin X-P, Zhou Y, Chen Y, Li N-N, Wu X-T. XRCC3 Thr241Met polymorphism and gastric cancer susceptibility: A meta-analysis. Clinics and Research in Hepatology and Gastroenterology. 2014;38(2):226-234.

19. Sun H, Qiao Y, Zhang X, Xu L, Jia X, Sun D, et al. XRCC3 Thr241Met polymorphism with lung cancer and bladder cancer: A meta-analysis. Cancer Science. 2010;101(8):1777-1782.

20. Jacobsen NR, Raaschou-Nielsen O, Nexo B, WALLIN H, Overvad K, Tjonneland A, et al. XRCC3 polymorphisms and risk of lung cancer. Cancer Lett. 2004;213(4):213-24.

21. Manuguerra M, Saletta F, Karagas MR, Berwick M, Veglia F, Vineis P, et al. XRCC3 and XPD/ERCC2 single nucleotide polymorphisms and the risk of cancer: A huge review. American Journal of Epidemiology. 2006;164(4):297-302.

22. Fan J, Fan Y, Kang X, Zhao L. XRCC3 T241M polymorphism and melanoma skin cancer risk: A meta-analysis. Oncology Letters. 2015;9(5):2425-2429.

23. Dos Reis MB, Losi-Guembarovski R, de Souza Fonseca Ribeiro EM, Cavalli IJ, Morita MC, Ramos GH, et al. Allelic variants of XRCC1 and XRCC3 repair genes and susceptibility of oral cancer in Brazilian patients. J Oral Pathol Med. 2012;42(2):180-185.

24. Li F, Li C, Jiang Z, Ma N, Gao X. XRCC3 T241M polymorphism and bladder cancer risk: A meta-analysis. Basic and Translational Science. 2011;77(2):511-15.

25. Cheng S, Wang L, Wang L, Wang Z. Association of XRCC3 gene rs861539 polymorphism with gastric cancer risk: Evidence from a case-control study and a meta-analysis. Int J Clin Exp Pathol. 2015;8(2):1919-1919.

26. Su Y, Zhang H, Xu F, Kong J, Yu H, Qian B. DNA repair gene polymorphisms in relation to non-small cell lung cancer survival. Cell Physiol Biochem. 2015;36(4):1419-1429.

27. Lee S-A, Lee K-M, Park SK, Choi J-Y, Kim B, Nam J, et al. Genetic polymorphism of XRCC3 Thr241Met and breast cancer risk: Case-control study in Korean women and meta-analysis of 12 studies. Breast Cancer Res Treat. 2007;103(1):71–76.

28. Qureshi Z, Mahjabeen I, Baig RM, Kayani MA. Correlation between selected XRCC2, XRCC3 and RAD51 gene polymorphisms and primary breast cancer in women in pakistan. Asian Pac J Cancer Prev. 2014;15(23):10225-10229.

29. Zhan P, Wang Q, Qian Q, Yu L-K. XRCC3 Thr241Met gene polymorphisms and lung cancer risk: A meta-analysis. Journal of Experimental and Clinical Cancer Research. 2013;32(1):1.

30. Han S, Zhang HT, Wang Z, Xie Y, Tang R, Mao Y, et al. DNA repair gene XRCC3 polymorphisms and cancer risk: A meta-analysis of 48 case-control studies. European Journal of Human Genetics. 2006;14(10):1136–1144.
31. Bastos HN, Antão MR, Silva SN, Azevedo AP, Manita I, Teixeira V, et al. Association of polymorphisms in genes of the homologous recombination DNA repair pathway and thyroid cancer risk. Thyroid. 2009;19(10):1067-75. DOI: 10.1089/thy.2009.0099

32. Wang X, Zhang K, Liu X, Liu B, Wang Z. Association between XRCC1 and XRCC3 gene polymorphisms and risk of thyroid cancer. Int J Clin Exp Pathol. 2015;8(3):3160-3167.

33. Fang F, Wang J, Yao L, Yu XF, Yu L, Yu L. Relationship between XRCC3 T241M polymorphism and gastric cancer risk: A meta-analysis. Med Oncol. 2011;28(4):999-1003. DOI: 10.1007/s12032-010-9591-3

© 2016 Cabral et al.; This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Peer-review history:
The peer review history for this paper can be accessed here:
http://sciedomain.org/review-history/14448